Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
äŒæ¥ã³ãŒãDXR
äŒç€ŸåDaxor Corp
äžå Žæ¥Jul 25, 1983
æé«çµå¶è²¬ä»»è
ãCEOãFeldschuh (Michael Richard)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jul 25
æ¬ç€Ÿæåšå°Suite 7120
éœåžNEW YORK
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·10118
é»è©±çªå·12122440555
ãŠã§ããµã€ãhttps://www.daxor.com/
äŒæ¥ã³ãŒãDXR
äžå Žæ¥Jul 25, 1983
æé«çµå¶è²¬ä»»è
ãCEOãFeldschuh (Michael Richard)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã